ASCO: New antibody-drug conjugate reveals promising security and response charges for sufferers with uncommon blood most cancers. Credit score: The College of Texas MD Anderson Most cancers Heart
The primary-in-class antibody-drug conjugate (ADC) pivekimab sunirine (PVEK) demonstrated promising efficacy and excessive response charges for sufferers with blastic plasmacytoid dendritic cell neoplasm (BPDCN), based on information from a Section I/II examine led by researchers from The College of Texas MD Anderson Most cancers Heart.
These outcomes counsel that PVEK must be thought of a possible new commonplace therapy choice for sufferers with BPDCN, a uncommon, aggressive blood most cancers that includes the pores and skin, bone marrow and lymph nodes.
Findings from the CADENZA examine had been introduced on the 2025 American Society of Scientific Oncology (ASCO) Annual Assembly by Naveen Pemmaraju, who led the trial along with Naval Daver.
As a frontline therapy in 33 newly identified sufferers with BPDCN, researchers noticed an general response fee of 85%, together with an entire response fee of 70% with a median general survival of 16.6 months.
“Patients with BPDCN are in need of improved frontline therapies to treat their disease, so we’re very excited to see this trial going extremely well in terms of safety and efficacy,” Pemmaraju mentioned. “The responses we have observed make PVEK a strong candidate as a standard-of-care treatment.”
The present standard-of-care therapy for sufferers with BPDCN is tagraxofusp-erzs, which targets CD123 discovered at excessive ranges on sure most cancers cells, together with BPDCN. MD Anderson researchers helped advance tagraxofusp-erzs towards Meals and Drug Administration approval in 2018.
PVEK represents a subsequent era of CD123-targeted therapy. As an ADC, it really works by delivering a drug on to most cancers cells by concentrating on CD123 on the floor of BPDCN cells, leading to demise of the most cancers cells.
The worldwide multi-center trial enrolled a complete of 84 grownup sufferers with CD123-positive BPDCN. Of those sufferers, 33 sufferers had been newly identified, and 51 sufferers had relapsed or refractory BPDCN with one, two or three prior strains of remedy. Contributors obtained the remedy intravenously on day one in all a 21-day cycle in an outpatient setting.
The most typical unintended effects included peripheral edema, which was reversible and located to be manageable.
Given the outcomes of this trial, there’s potential for investigating mixture therapies of CD123-targeted agent PVEK with different remedies lively in BPDCN in future medical trials, Pemmaraju defined.
The medical trial was funded by AbbVie. Pemmaraju has served on the advisory board and as a guide for AbbVie. Daver has obtained analysis help and has served on the advisory board and as a guide for AbbVie.
Extra data:
Summary: conferences.asco.org/abstracts-presentations/244202
Offered by
College of Texas M. D. Anderson Most cancers Heart
Quotation:
Antibody-drug conjugate reveals promising security and response charges for sufferers with uncommon blood most cancers (2025, June 2)
retrieved 2 June 2025
from https://medicalxpress.com/information/2025-06-antibody-drug-conjugate-safety-response.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
